Publicaciones en colaboración con investigadores/as de Stanford University School of Medicine (17)

2023

  1. Chromatin insulation orchestrates matrix metalloproteinase gene cluster expression reprogramming in aggressive breast cancer tumors

    Molecular Cancer, Vol. 22, Núm. 1

  2. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 2, pp. 198-205

  3. TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease

    Nature Cardiovascular Research, Vol. 2, Núm. 2, pp. 144-158

  4. Worldwide survey on implantation of and outcomes for conduction system pacing with His bundle and left bundle branch area pacing leads

    Journal of Interventional Cardiac Electrophysiology, Vol. 66, Núm. 7, pp. 1589-1600

2022

  1. Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 10, Núm. 4, pp. 367-377

2021

  1. Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

    JAMA Oncology, Vol. 7, Núm. 4, pp. 573-584

  2. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

    Annals of Oncology, Vol. 31, Núm. 12, pp. 1623-1649

2019

  1. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer

    European Journal of Cancer, Vol. 120, pp. 1-9

2018

  1. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3126-3133

2017

  1. Eruptive keratoacanthomas associated with pembrolizumab therapy

    JAMA Dermatology, Vol. 153, Núm. 7, pp. 694-697

2016

  1. Clinical delineation of the PACS1-related syndrome-Report on 19 patients

    American Journal of Medical Genetics, Part A, Vol. 170, Núm. 3, pp. 670-675

2015

  1. Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer

    Current Medical Research and Opinion, Vol. 31, Núm. 6, pp. 1129-1137

2013

  1. Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial

    Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649

2012

  1. Reduction of NADPH-oxidase activity ameliorates the cardiovascular phenotype in a mouse model of Williams-Beuren Syndrome

    PLoS Genetics, Vol. 8, Núm. 2

2007

  1. Differential sensitivity to apoptosis among the cells that contribute to the atherosclerotic disease

    Biochemical and Biophysical Research Communications, Vol. 363, Núm. 2, pp. 444-450

2004

  1. Three mechanisms underlie KCNQ2/3 heteromeric potassium M-channel potentiation

    Journal of Neuroscience, Vol. 24, Núm. 41, pp. 9146-9152